Ignite Creation Date:
2025-12-24 @ 11:59 AM
Ignite Modification Date:
2025-12-30 @ 1:29 AM
Study NCT ID:
NCT05363761
Status:
RECRUITING
Last Update Posted:
2023-03-21
First Post:
2022-05-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
Sponsor:
Neurotronic, Inc.
Organization:
Study Overview
Official Title:
Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR III Trial)
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NECTAR III
Brief Summary:
This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.
Detailed Description:
This study is a prospective, single-arm, multi-center trial to evaluate the safety and performance of use of the Neurotronic Infusion Catheter for chemical denervation of renal and hepatic arteries for treatment of patients with type 2 diabetes, hypertension, and obesity.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
True
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: